scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Sold by J. Goldman & Co LP

J. Goldman & Co LP trimmed its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 11.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,219,127 shares of the company's stock after selling 160,866 shares during the period. J. Goldman & Co LP owned 2.44% of scPharmaceuticals worth $4,316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Legato Capital Management LLC purchased a new position in scPharmaceuticals in the 4th quarter valued at about $37,000. China Universal Asset Management Co. Ltd. purchased a new position in scPharmaceuticals in the 4th quarter valued at about $38,000. Price T Rowe Associates Inc. MD purchased a new position in scPharmaceuticals in the 4th quarter valued at about $54,000. Wells Fargo & Company MN boosted its position in scPharmaceuticals by 110.5% in the 4th quarter. Wells Fargo & Company MN now owns 18,407 shares of the company's stock valued at $65,000 after buying an additional 9,663 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in scPharmaceuticals in the 4th quarter valued at about $66,000. 89.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SCPH shares. Maxim Group decreased their price objective on shares of scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Thursday, March 20th.

scPharmaceuticals Stock Up 11.8%

Shares of SCPH stock traded up $0.34 during trading hours on Friday, hitting $3.22. 1,202,096 shares of the company were exchanged, compared to its average volume of 367,483. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. scPharmaceuticals Inc. has a one year low of $1.94 and a one year high of $5.65. The business's 50-day simple moving average is $2.60 and its two-hundred day simple moving average is $3.16. The stock has a market capitalization of $169.99 million, a price-to-earnings ratio of -1.69 and a beta of 0.17.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The company had revenue of $11.75 million for the quarter, compared to the consensus estimate of $11.63 million. Sell-side analysts predict that scPharmaceuticals Inc. will post -1.53 EPS for the current fiscal year.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.